| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.664 | 0.005 | 0.773 | Anticonvulsant | 0.591 0.007 DBMET01673 0.773 0.004 DBMET00250 | DBMET00250 | |
| 0.593 | 0.037 | 0.639 | Caspase 9 stimulant | 0.532 0.049 DBMET01673 0.639 0.031 DBMET00250 | DBMET00250 | |
| 0.501 | 0.02 | 0.519 | Caspase 3 stimulant | 0.496 0.021 DBMET01673 0.519 0.018 DBMET00250 | DBMET00250 | |
| 0.412 | 0.027 | 0.412 | Cardiotonic | 0.38 0.032 DBMET01673 0.352 0.039 DBMET00250 | ||
| 0.383 | 0.028 | 0.444 | Hypolipemic | 0.417 0.022 DBMET01673 0.444 0.018 DBMET00250 | DBMET00250 | |
| 0.373 | 0.028 | 0.378 | Vasodilator | 0.35 0.033 DBMET01673 0.378 0.027 DBMET00250 | DBMET00250 | |
| 0.335 | 0.023 | 0.382 | Dual specificity phosphatase 3 inhibitor | 0.339 0.022 DBMET01673 0.382 0.016 DBMET00250 | DBMET00250 | |
| 0.313 | 0.013 | 0.504 | Insulin sensitizer | 0.359 0.009 DBMET01673 0.504 0.004 DBMET00250 | DBMET00250 | |
| 0.338 | 0.062 | 0.338 | Vasodilator, coronary | 0.313 0.077 DBMET01673 0.275 0.11 DBMET00250 | ||
| 0.33 | 0.083 | 0.378 | Transcription factor NF kappa B inhibitor | 0.343 0.079 DBMET01673 0.378 0.069 DBMET00250 | DBMET00250 | |
| 0.269 | 0.034 | 0.36 | Dual specificity phosphatase inhibitor | 0.299 0.029 DBMET01673 0.36 0.019 DBMET00250 | DBMET00250 | |
| 0.314 | 0.079 | 0.314 | Calcium channel activator | 0.248 0.15 DBMET01673 0.239 0.161 DBMET00250 | ||
| 0.344 | 0.126 | 0.561 | Cyclophilin D inhibitor | 0.455 0.065 DBMET01673 0.561 0.035 DBMET00250 | DBMET00250 | |
| 0.203 | 0.006 | 0.203 | Toll-Like receptor 3 antagonist | 0.183 0.008 DBMET01673 0.135 0.02 DBMET00250 | ||
| 0.201 | 0.005 | 0.201 | Calcium channel L-type blocker | 0.11 0.02 DBMET01673 0.098 0.026 DBMET00250 | ||
| 0.312 | 0.127 | 0.411 | Antibacterial | 0.41 0.072 DBMET01673 0.411 0.072 DBMET00250 | DBMET00250 | |
| 0.317 | 0.143 | 0.317 | Calcium channel L-type activator | 0.253 0.202 DBMET00250 | ||
| 0.18 | 0.008 | 0.28 | Peroxisome proliferator-activated receptor gamma agonist | 0.195 0.007 DBMET01673 0.28 0.005 DBMET00250 | DBMET00250 | |
| 0.195 | 0.032 | 0.302 | Cell wall synthesis inhibitor | 0.258 0.014 DBMET01673 0.302 0.01 DBMET00250 | DBMET00250 | |
| 0.192 | 0.045 | 0.263 | Protein kinase stimulant | 0.255 0.025 DBMET01673 0.263 0.023 DBMET00250 | DBMET00250 | |
| 0.23 | 0.089 | 0.353 | Hypoglycemic | 0.263 0.069 DBMET01673 0.353 0.037 DBMET00250 | DBMET00250 | |
| 0.175 | 0.042 | 0.175 | Calcium channel blocker | |||
| 0.142 | 0.014 | 0.187 | Ornithine decarboxylase inhibitor | 0.134 0.017 DBMET01673 0.187 0.005 DBMET00250 | DBMET00250 | |
| 0.175 | 0.065 | 0.295 | Thrombolytic | 0.223 0.042 DBMET01673 0.295 0.025 DBMET00250 | DBMET00250 | |
| 0.144 | 0.034 | 0.198 | GABA C receptor antagonist | 0.176 0.019 DBMET01673 0.198 0.013 DBMET00250 | DBMET00250 | |
| 0.126 | 0.02 | 0.168 | Glutathione S-transferase inhibitor | 0.151 0.012 DBMET01673 0.168 0.009 DBMET00250 | DBMET00250 | |
| 0.142 | 0.04 | 0.143 | GABA receptor agonist | 0.117 0.059 DBMET01673 0.143 0.04 DBMET00250 | DBMET00250 | |
| 0.201 | 0.1 | 0.434 | Platelet antagonist | 0.223 0.086 DBMET01673 0.434 0.021 DBMET00250 | DBMET00250 | |
| 0.115 | 0.018 | 0.199 | Sphingosine 1-phosphate receptor 4 agonist | 0.149 0.009 DBMET01673 0.199 0.004 DBMET00250 | DBMET00250 | |
| 0.126 | 0.031 | 0.126 | Acetylcholine M3 receptor agonist | 0.081 0.059 DBMET01673 0.071 0.07 DBMET00250 | ||
| 0.1 | 0.009 | 0.1 | Nitric oxide donor | 0.094 0.012 DBMET01673 0.095 0.011 DBMET00250 | ||
| 0.127 | 0.037 | 0.142 | Sphingomyelinase inhibitor | 0.142 0.028 DBMET01673 0.088 0.074 DBMET00250 | DBMET01673 | |
| 0.176 | 0.09 | 0.176 | Anesthetic general | 0.171 0.094 DBMET00250 | ||
| 0.138 | 0.053 | 0.148 | Vanilloid 1 agonist | 0.144 0.045 DBMET01673 0.148 0.04 DBMET00250 | DBMET00250 | |
| 0.212 | 0.128 | 0.261 | Lipoxygenase inhibitor | 0.209 0.131 DBMET01673 0.261 0.093 DBMET00250 | DBMET00250 | |
| 0.105 | 0.022 | 0.105 | Amidase inhibitor | 0.086 0.033 DBMET01673 0.092 0.029 DBMET00250 | ||
| 0.105 | 0.024 | 0.105 | 5 Hydroxytryptamine uptake inhibitor | 0.072 0.037 DBMET01673 | ||
| 0.091 | 0.014 | 0.181 | Peroxisome proliferator-activated receptor alpha agonist | 0.099 0.012 DBMET01673 0.181 0.005 DBMET00250 | DBMET00250 | |
| 0.195 | 0.125 | 0.237 | 5 Hydroxytryptamine release stimulant | 0.237 0.096 DBMET01673 0.198 0.123 DBMET00250 | DBMET01673 | |
| 0.136 | 0.071 | 0.167 | Farnesoid X receptor antagonist | 0.167 0.037 DBMET01673 0.144 0.06 DBMET00250 | DBMET01673 | |
| 0.107 | 0.043 | 0.107 | Calcium antagonist | |||
| 0.107 | 0.044 | 0.114 | Interleukin 12 antagonist | 0.092 0.069 DBMET01673 0.114 0.035 DBMET00250 | DBMET00250 | |
| 0.114 | 0.052 | 0.114 | Carbonic anhydrase XV inhibitor | 0.103 0.064 DBMET01673 | ||
| 0.164 | 0.103 | 0.164 | MAP kinase kinase 5 inhibitor | |||
| 0.078 | 0.019 | 0.078 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.074 | 0.019 | 0.106 | Sphingosine kinase 2 inhibitor | 0.106 0.006 DBMET01673 | DBMET01673 | |
| 0.116 | 0.061 | 0.116 | Calcium channel (voltage-sensitive) blocker | |||
| 0.075 | 0.021 | 0.096 | Sphingosine 1-phosphate receptor 3 antagonist | 0.096 0.009 DBMET01673 0.084 0.014 DBMET00250 | DBMET01673 | |
| 0.064 | 0.01 | 0.064 | Cytokine production stimulant | 0.055 0.018 DBMET01673 | ||
| 0.079 | 0.028 | 0.083 | Beta adrenoreceptor antagonist | 0.083 0.025 DBMET01673 0.069 0.04 DBMET00250 | DBMET01673 | |
| 0.152 | 0.103 | 0.214 | Phospholipase C inhibitor | 0.181 0.059 DBMET01673 0.214 0.036 DBMET00250 | DBMET00250 | |
| 0.058 | 0.011 | 0.107 | GABA uptake inhibitor | 0.102 0.004 DBMET01673 0.107 0.004 DBMET00250 | DBMET00250 | |
| 0.062 | 0.015 | 0.132 | Sphingosine 1-phosphate receptor agonist | 0.099 0.005 DBMET01673 0.132 0.004 DBMET00250 | DBMET00250 | |
| 0.136 | 0.094 | 0.226 | Protein-tyrosine phosphatase inhibitor | 0.159 0.07 DBMET01673 0.226 0.038 DBMET00250 | DBMET00250 | |
| 0.055 | 0.016 | 0.131 | Sphingosine 1-phosphate receptor 1 agonist | 0.099 0.004 DBMET01673 0.131 0.004 DBMET00250 | DBMET00250 | |
| 0.084 | 0.046 | 0.1 | Na+ K+ transporting ATPase inhibitor | 0.098 0.033 DBMET01673 0.1 0.031 DBMET00250 | DBMET00250 | |
| 0.108 | 0.075 | 0.118 | Photosensitizer | 0.118 0.06 DBMET00250 | DBMET00250 | |
| 0.054 | 0.024 | 0.054 | Oleamide hydrolase inhibitor | |||
| 0.06 | 0.036 | 0.065 | Beta 1 adrenoreceptor antagonist | 0.065 0.031 DBMET01673 | DBMET01673 | |
| 0.127 | 0.106 | 0.2 | Phospholipase A2 inhibitor | 0.142 0.083 DBMET01673 0.2 0.042 DBMET00250 | DBMET00250 | |
| 0.191 | 0.171 | 0.191 | Nootropic | 0.19 0.172 DBMET01673 | ||
| 0.059 | 0.041 | 0.095 | Sphingosine kinase inhibitor | 0.095 0.009 DBMET01673 | DBMET01673 | |
| 0.038 | 0.023 | 0.076 | Sphingosine 1-phosphate receptor 3 agonist | 0.076 0.009 DBMET01673 0.064 0.011 DBMET00250 | DBMET01673 | |
| 0.065 | 0.051 | 0.114 | Potassium channel large-conductance Ca-activated activator | 0.11 0.02 DBMET01673 0.114 0.018 DBMET00250 | DBMET00250 | |
| 0.027 | 0.014 | 0.027 | Lysophosphatidic acid receptor 1 agonist | 0.023 0.022 DBMET01673 0.024 0.019 DBMET00250 | ||
| 0.059 | 0.047 | 0.059 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.08 | 0.069 | 0.094 | Vanilloid agonist | 0.094 0.041 DBMET01673 0.09 0.047 DBMET00250 | DBMET01673 | |
| 0.049 | 0.039 | 0.049 | H+/K+-transporting ATPase inhibitor | |||
| 0.027 | 0.018 | 0.117 | Kynurenine 3 monooxygenase inhibitor | 0.026 0.018 DBMET01673 0.117 0.003 DBMET00250 | DBMET00250 | |
| 0.016 | 0.007 | 0.016 | Lysophosphatidic acid receptor 3 agonist | |||
| 0.105 | 0.096 | 0.142 | Toll-Like receptor 2 antagonist | 0.103 0.099 DBMET01673 0.142 0.058 DBMET00250 | DBMET00250 | |
| 0.033 | 0.024 | 0.087 | Peroxisome proliferator-activated receptor delta agonist | 0.038 0.019 DBMET01673 0.087 0.007 DBMET00250 | DBMET00250 | |
| 0.048 | 0.04 | 0.051 | Beta 2 adrenoreceptor antagonist | 0.051 0.035 DBMET01673 | DBMET01673 | |
| 0.067 | 0.059 | 0.07 | Thrombin inhibitor | 0.069 0.056 DBMET01673 0.07 0.055 DBMET00250 | DBMET00250 | |
| 0.071 | 0.064 | 0.077 | Keratolytic | 0.072 0.061 DBMET01673 0.077 0.053 DBMET00250 | DBMET00250 | |
| 0.033 | 0.026 | 0.057 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.039 0.017 DBMET01673 0.057 0.007 DBMET00250 | DBMET00250 | |
| 0.067 | 0.061 | 0.109 | Glycine receptor agonist | 0.086 0.031 DBMET01673 0.109 0.016 DBMET00250 | DBMET00250 | |
| 0.033 | 0.029 | 0.038 | Ceramide glucosyltransferase inhibitor | 0.038 0.02 DBMET01673 | DBMET01673 | |
| 0.077 | 0.073 | 0.077 | Histamine H2 receptor antagonist | |||
| 0.1 | 0.096 | 0.11 | Cholinergic antagonist | 0.11 0.083 DBMET01673 | DBMET01673 | |
| 0.052 | 0.051 | 0.052 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.025 | 0.024 | 0.034 | Retinoid X gamma receptor antagonist | 0.029 0.014 DBMET01673 0.034 0.008 DBMET00250 | DBMET00250 | |
| 0.086 | 0.085 | 0.498 | GABA C receptor agonist | 0.197 0.021 DBMET01673 0.498 0.004 DBMET00250 | DBMET00250 | |
| 0.037 | 0.037 | 0.045 | Dopamine D2 agonist | 0.045 0.03 DBMET01673 | DBMET01673 | |
| 0.043 | 0.048 | 0.061 | Lysophosphatidic acid 3 receptor antagonist | 0.061 0.021 DBMET00250 | DBMET00250 | |
| 0.081 | 0.088 | 0.101 | Topoisomerase I inhibitor | 0.098 0.072 DBMET01673 0.101 0.069 DBMET00250 | DBMET00250 | |
| 0.029 | 0.038 | 0.042 | Kinesin-like protein 1 inhibitor | 0.042 0.02 DBMET01673 0.033 0.031 DBMET00250 | DBMET01673 | |
| 0.029 | 0.038 | 0.042 | Kinesin antagonist | 0.042 0.02 DBMET01673 0.033 0.031 DBMET00250 | DBMET01673 | |
| 0.127 | 0.14 | 0.275 | Interleukin antagonist | 0.184 0.093 DBMET01673 0.275 0.054 DBMET00250 | DBMET00250 | |
| 0.067 | 0.081 | 0.091 | Sphingosine 1-phosphate receptor antagonist | 0.076 0.054 DBMET01673 0.091 0.029 DBMET00250 | DBMET00250 | |
| 0.034 | 0.048 | 0.061 | Sphingosine kinase 1 inhibitor | 0.061 0.009 DBMET01673 | DBMET01673 | |
| 0.126 | 0.141 | 0.153 | Ca2+-transporting ATPase inhibitor | 0.145 0.057 DBMET01673 0.153 0.037 DBMET00250 | DBMET00250 | |
| 0.234 | 0.252 | 0.265 | 5 Hydroxytryptamine release inhibitor | 0.265 0.207 DBMET01673 | DBMET01673 | |
| 0.041 | 0.064 | 0.068 | Cannabinoid CB1 receptor agonist | 0.068 0.037 DBMET01673 | DBMET01673 | |
| 0.083 | 0.107 | 0.159 | Adenylate kinase inhibitor | 0.097 0.072 DBMET01673 0.159 0.023 DBMET00250 | DBMET00250 | |
| 0.026 | 0.052 | 0.041 | Toll-Like receptor 2 agonist | 0.041 0.028 DBMET00250 | DBMET00250 | |
| 0.043 | 0.07 | 0.088 | Thromboxane synthase inhibitor | 0.059 0.028 DBMET01673 0.088 0.009 DBMET00250 | DBMET00250 | |
| 0.154 | 0.181 | 0.233 | Superoxide dismutase inhibitor | 0.233 0.086 DBMET01673 0.208 0.109 DBMET00250 | DBMET01673 | |
| 0.114 | 0.143 | 0.169 | Sphingosine 1-phosphate receptor 5 antagonist | 0.169 0.035 DBMET01673 0.152 0.058 DBMET00250 | DBMET01673 | |
| 0.104 | 0.134 | 0.188 | Anticoagulant | 0.188 0.058 DBMET00250 | DBMET00250 | |
| 0.061 | 0.099 | 0.085 | Myeloperoxidase inhibitor | 0.085 0.057 DBMET01673 | DBMET01673 | |
| 0.027 | 0.064 | 0.048 | Retinoid X receptor antagonist | 0.048 0.014 DBMET00250 | DBMET00250 | |
| 0.075 | 0.113 | 0.087 | Glutamate release inhibitor | 0.087 0.07 DBMET00250 | DBMET00250 | |
| 0.051 | 0.092 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.057 DBMET01673 | DBMET01673 | |
| 0.014 | 0.056 | 0.027 | Retinoid X beta receptor antagonist | 0.019 0.018 DBMET01673 0.027 0.006 DBMET00250 | DBMET00250 | |
| 0.022 | 0.068 | 0.039 | Peroxisome proliferator-activated receptor delta antagonist | 0.039 0.015 DBMET00250 | DBMET00250 | |
| 0.023 | 0.07 | 0.039 | Retinoid X alpha receptor antagonist | 0.039 0.016 DBMET00250 | DBMET00250 | |
| 0.053 | 0.1 | 0.077 | CDC25A inhibitor | 0.077 0.046 DBMET00250 | DBMET00250 | |
| 0.031 | 0.079 | 0.091 | Plasminogen activator inhibitor antagonist | 0.091 0.012 DBMET00250 | DBMET00250 | |
| 0.172 | 0.221 | 0.27 | 5 Hydroxytryptamine uptake stimulant | 0.27 0.063 DBMET00250 | DBMET00250 | |
| 0.061 | 0.11 | 0.09 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.09 0.049 DBMET01673 | DBMET01673 | |
| 0.013 | 0.065 | 0.021 | Prostaglandin F2 alpha agonist | 0.021 0.018 DBMET00250 | DBMET00250 | |
| 0.059 | 0.115 | 0.098 | GABA B receptor agonist | 0.084 0.034 DBMET01673 0.098 0.018 DBMET00250 | DBMET00250 | |
| 0.007 | 0.066 | 0.04 | Prostaglandin H2 antagonist | 0.04 0.005 DBMET00250 | DBMET00250 | |
| 0.067 | 0.131 | 0.082 | Estrogen-related receptor beta agonist | 0.082 0.059 DBMET01673 | DBMET01673 | |
| 0.039 | 0.104 | 0.056 | Sphingosine 1-phosphate receptor 1 antagonist | 0.056 0.037 DBMET00250 | DBMET00250 | |
| 0.009 | 0.077 | 0.049 | Arginase inhibitor | 0.036 0.026 DBMET01673 0.049 0.016 DBMET00250 | DBMET00250 | |
| 0.118 | 0.187 | 0.185 | Succinate dehydrogenase inhibitor | 0.156 0.102 DBMET01673 0.185 0.063 DBMET00250 | DBMET00250 | |
| 0.117 | 0.188 | 0.178 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.178 0.096 DBMET01673 | DBMET01673 | |
| 0.074 | 0.146 | 0.14 | Bone formation stimulant | 0.14 0.067 DBMET01673 0.135 0.071 DBMET00250 | DBMET01673 | |
| 0.099 | 0.171 | 0.126 | Thiol protease inhibitor | 0.126 0.104 DBMET01673 0.12 0.118 DBMET00250 | DBMET01673 | |
| 0.152 | 0.224 | 0.201 | Neuropeptide Y2 antagonist | 0.19 0.138 DBMET01673 0.201 0.118 DBMET00250 | DBMET00250 | |
| 0.163 | 0.239 | 0.23 | Immunosuppressant | 0.23 0.166 DBMET01673 0.229 0.167 DBMET00250 | DBMET01673 | |
| 0.111 | 0.189 | 0.161 | Non-steroidal antiinflammatory agent | 0.161 0.103 DBMET00250 | DBMET00250 | |
| 0.047 | 0.125 | 0.071 | Metalloproteinase-2 inhibitor | 0.071 0.064 DBMET00250 | DBMET00250 | |
| 0.063 | 0.141 | 0.084 | Lanosterol 14 alpha demethylase inhibitor | 0.084 0.082 DBMET00250 | DBMET00250 | |
| 0.095 | 0.174 | 0.127 | Sphingosine 1-phosphate receptor 2 antagonist | 0.125 0.084 DBMET01673 0.127 0.08 DBMET00250 | DBMET00250 | |
| 0.028 | 0.107 | 0.043 | GABA B receptor antagonist | 0.043 0.028 DBMET00250 | DBMET00250 | |
| 0.036 | 0.117 | 0.081 | Sphingosine 1-phosphate receptor 5 agonist | 0.05 0.049 DBMET01673 0.081 0.012 DBMET00250 | DBMET00250 | |
| 0.011 | 0.092 | 0.061 | GP IIb/IIIa receptor antagonist | 0.061 0.027 DBMET00250 | DBMET00250 | |
| 0.111 | 0.194 | 0.149 | Platelet aggregation inhibitor | 0.149 0.13 DBMET00250 | DBMET00250 | |
| 0.047 | 0.135 | 0.084 | Glutamate (mGluR6) antagonist | 0.084 0.02 DBMET00250 | DBMET00250 | |
| 0.035 | 0.123 | 0.161 | Catalase inhibitor | 0.064 0.061 DBMET01673 0.161 0.024 DBMET00250 | DBMET00250 | |
| 0.064 | 0.153 | 0.119 | MAP kinase kinase 1 inhibitor | 0.119 0.036 DBMET01673 | DBMET01673 | |
| 0.016 | 0.109 | 0.032 | Estrogen-related receptor gamma antagonist | 0.032 0.013 DBMET01673 | DBMET01673 | |
| 0.018 | 0.119 | 0.042 | Adenosine deaminase inhibitor | 0.042 0.038 DBMET01673 | DBMET01673 | |
| 0.018 | 0.119 | 0.067 | Ornithine carbamoyltransferase inhibitor | 0.067 0.027 DBMET01673 0.056 0.034 DBMET00250 | DBMET01673 | |
| 0.106 | 0.21 | 0.171 | Lipocortins synthesis antagonist | 0.171 0.079 DBMET00250 | DBMET00250 | |
| 0.008 | 0.114 | 0.02 | Glutamate (mGluR1a) agonist | 0.02 0.018 DBMET00250 | DBMET00250 | |
| 0.023 | 0.13 | 0.074 | Alcohol oxidase inhibitor | 0.056 0.039 DBMET01673 0.074 0.027 DBMET00250 | DBMET00250 | |
| 0.045 | 0.155 | 0.144 | Aminopeptidase B inhibitor | 0.118 0.054 DBMET01673 0.144 0.04 DBMET00250 | DBMET00250 | |
| 0.018 | 0.13 | 0.066 | Thromboxane A2 antagonist | 0.066 0.024 DBMET00250 | DBMET00250 | |
| 0.135 | 0.249 | 0.266 | Cholesterol antagonist | 0.266 0.114 DBMET00250 | DBMET00250 | |
| 0.026 | 0.14 | 0.095 | Aconitate hydratase inhibitor | 0.095 0.009 DBMET00250 | DBMET00250 | |
| 0.033 | 0.15 | 0.111 | NMDA receptor agonist | 0.111 0.016 DBMET00250 | DBMET00250 | |
| 0.101 | 0.218 | 0.169 | Immunostimulant | 0.169 0.14 DBMET00250 | DBMET00250 | |
| 0.021 | 0.139 | 0.046 | Glutamate (mGluR8) agonist | 0.046 0.015 DBMET00250 | DBMET00250 | |
| 0.026 | 0.144 | 0.049 | Glutamate (mGluR group III) antagonist | 0.049 0.022 DBMET00250 | DBMET00250 | |
| 0.068 | 0.186 | 0.136 | Aldehyde dehydrogenase inhibitor | 0.136 0.057 DBMET01673 0.133 0.059 DBMET00250 | DBMET01673 | |
| 0.016 | 0.136 | 0.037 | Glutamate (mGluR3) antagonist | 0.037 0.025 DBMET00250 | DBMET00250 | |
| 0.066 | 0.188 | 0.094 | DOPA decarboxylase inhibitor | 0.094 0.09 DBMET00250 | DBMET00250 | |
| 0.143 | 0.269 | 0.278 | Insulysin inhibitor | 0.278 0.073 DBMET00250 | DBMET00250 | |
| 0.024 | 0.15 | 0.122 | Carbamoyl phosphate synthetase inhibitor | 0.062 0.041 DBMET01673 0.122 0.015 DBMET00250 | DBMET00250 | |
| 0.08 | 0.207 | 0.136 | Arachidonic acid antagonist | 0.136 0.105 DBMET00250 | DBMET00250 | |
| 0.019 | 0.147 | 0.066 | Thromboxane antagonist | 0.066 0.028 DBMET00250 | DBMET00250 | |
| 0.031 | 0.161 | 0.16 | Glutamate decarboxylase inhibitor | 0.077 0.047 DBMET01673 0.16 0.011 DBMET00250 | DBMET00250 | |
| 0.057 | 0.186 | 0.089 | AMP-activated protein kinase stimulant | 0.089 0.088 DBMET01673 | DBMET01673 | |
| 0.021 | 0.151 | 0.054 | NMDA receptor glycine site agonist | 0.054 0.053 DBMET00250 | DBMET00250 | |
| 0.056 | 0.186 | 0.085 | ABCA1 expression enhancer | 0.085 0.075 DBMET00250 | DBMET00250 | |
| 0.056 | 0.187 | 0.087 | Electrolyte absorption antagonist | 0.087 0.079 DBMET00250 | DBMET00250 | |
| 0.011 | 0.147 | 0.024 | Thyroid hormone agonist | 0.024 0.022 DBMET00250 | DBMET00250 | |
| 0.084 | 0.221 | 0.288 | Growth hormone agonist | 0.288 0.035 DBMET00250 | DBMET00250 | |
| 0.069 | 0.207 | 0.157 | Psychostimulant | 0.157 0.11 DBMET00250 | DBMET00250 | |
| 0.015 | 0.156 | 0.032 | Carboxypeptidase B inhibitor | 0.032 0.024 DBMET00250 | DBMET00250 | |
| 0.037 | 0.178 | 0.101 | GABA aminotransferase inhibitor | 0.101 0.026 DBMET00250 | DBMET00250 | |
| 0.134 | 0.278 | 0.271 | Antithrombotic | 0.271 0.11 DBMET00250 | DBMET00250 | |
| 0.007 | 0.151 | 0.02 | Integrin alphaVbeta3 antagonist | 0.02 0.018 DBMET00250 | DBMET00250 | |
| 0.039 | 0.184 | 0.102 | Protein-tyrosine phosphatase 1B inhibitor | 0.102 0.076 DBMET00250 | DBMET00250 | |
| 0.024 | 0.173 | 0.053 | Glutamate (mGluR4) antagonist | 0.053 0.018 DBMET00250 | DBMET00250 | |
| 0.034 | 0.186 | 0.1 | Potassium channel (Ca-activated) activator | 0.086 0.069 DBMET01673 0.1 0.055 DBMET00250 | DBMET00250 | |
| 0.066 | 0.22 | 0.201 | Angiogenesis stimulant | 0.168 0.111 DBMET01673 0.201 0.094 DBMET00250 | DBMET00250 | |
| 0.019 | 0.182 | 0.042 | Glutamate (mGluR8) antagonist | 0.042 0.015 DBMET00250 | DBMET00250 | |
| 0.015 | 0.182 | 0.041 | Estrogen-related receptor beta antagonist | 0.041 0.01 DBMET01673 | DBMET01673 | |
| 0.081 | 0.255 | 0.125 | Adenylate cyclase stimulant | 0.125 0.113 DBMET00250 | DBMET00250 | |
| 0.008 | 0.182 | 0.03 | Prostaglandin D2 agonist | 0.03 0.023 DBMET00250 | DBMET00250 | |
| 0.066 | 0.254 | 0.096 | Factor V inhibitor | 0.096 0.079 DBMET00250 | DBMET00250 | |
| 0.006 | 0.204 | 0.025 | Lysine carboxypeptidase inhibitor | 0.025 0.021 DBMET00250 | DBMET00250 | |
| 0.05 | 0.247 | 0.106 | Nav1.4 sodium channel blocker | 0.106 0.067 DBMET00250 | DBMET00250 | |
| 0.02 | 0.238 | 0.048 | Glucose-6-phosphate isomerase inhibitor | 0.048 0.032 DBMET00250 | DBMET00250 | |
| 0.031 | 0.253 | 0.116 | Glutamate dehydrogenase inhibitor | 0.116 0.024 DBMET00250 | DBMET00250 | |
| 0.114 | 0.339 | 0.203 | Peptidyltransferase inhibitor | 0.203 0.096 DBMET01673 0.192 0.11 DBMET00250 | DBMET01673 | |
| 0.033 | 0.258 | 0.063 | Caspase 9 inhibitor | 0.063 0.042 DBMET00250 | DBMET00250 | |
| 0.015 | 0.243 | 0.098 | Phosphofructokinase-1 inhibitor | 0.098 0.033 DBMET00250 | DBMET00250 | |
| 0.123 | 0.353 | 0.226 | Tyrosine 3 hydroxylase inhibitor | 0.226 0.095 DBMET00250 | DBMET00250 | |
| 0.079 | 0.315 | 0.159 | Neurotrophic factor enhancer | 0.159 0.124 DBMET01673 | DBMET01673 | |
| 0.127 | 0.367 | 0.327 | Interleukin 2 agonist | 0.276 0.092 DBMET01673 0.327 0.057 DBMET00250 | DBMET00250 | |
| 0.02 | 0.298 | 0.072 | Aminopeptidase I inhibitor | 0.072 0.051 DBMET00250 | DBMET00250 | |
| 0.109 | 0.392 | 0.262 | Apoptosis antagonist | 0.262 0.116 DBMET00250 | DBMET00250 | |
| 0.015 | 0.318 | 0.073 | Phenylalanine 4-hydroxylase inhibitor | 0.073 0.043 DBMET00250 | DBMET00250 | |
| 0.034 | 0.339 | 0.112 | Triose-phosphate isomerase inhibitor | 0.112 0.037 DBMET00250 | DBMET00250 | |
| 0.046 | 0.354 | 0.089 | Hematopoietic | 0.089 0.051 DBMET00250 | DBMET00250 | |
| 0.067 | 0.412 | 0.17 | DNA synthesis inhibitor | 0.17 0.169 DBMET00250 | DBMET00250 | |
| 0.013 | 0.359 | 0.109 | Porphobilinogen synthase inhibitor | 0.109 0.032 DBMET00250 | DBMET00250 | |
| 0.017 | 0.385 | 0.085 | Alcohol dehydrogenase inhibitor | 0.085 0.071 DBMET00250 | DBMET00250 | |
| 0.023 | 0.409 | 0.109 | Ferrochelatase inhibitor | 0.109 0.062 DBMET00250 | DBMET00250 | |
| 0.071 | 0.496 | 0.171 | Catenin beta inhibitor | 0.171 0.065 DBMET00250 | DBMET00250 | |
| 0.013 | 0.501 | 0.068 | Prostaglandin F2 alpha antagonist | 0.068 0.034 DBMET00250 | DBMET00250 | |
| 0.038 | 0.607 | 0.106 | Folate antagonist | 0.106 0.055 DBMET00250 | DBMET00250 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |